Kura Oncology, Inc.
NASDAQ:KURABiotechnology
Healthcare
$7.34 +0.73%
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
52W Low $5.45High $12.49
Volume 2.46M
Average 1.66M
Income Statement
Follow revenue through to earnings.
Revenue
$67.48M
FY 2025 · Annual
+25.2% YoYOperating Income
-$303.63M
FY 2025 · Annual
Net Income
-$278.67M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 53.88M | 67.48M |
| Cost of Revenue | 0 | 0 | 849K | 0 | 57K |
| Gross Profit | 0 | 0 | (849K) | 53.88M | 67.43M |
| Gross Margin | — | — | — | 100.0% | 99.9% |
| Research & Development | 84.72M | 92.81M | 115.24M | 169.97M | 251.07M |
| Selling, General & Admin | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| Operating Expenses | 131.26M | 139.87M | 164.96M | 247.08M | 371.06M |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | 1.03M |
| EBITDA | (129.49M) | (134.85M) | (150.23M) | (169.5M) | (275.83M) |
| EBITDA Margin | — | — | — | -314.6% | -408.7% |
| Operating Income | (131.26M) | (139.87M) | (165.8M) | (193.2M) | (303.63M) |
| Operating Margin | — | — | — | -358.5% | -449.9% |
| Interest Income | 1.21M | 4.25M | 14.72M | 22.85M | 26.77M |
| Interest Expense | 414K | 229K | 1.55M | 1.62M | 1.51M |
| Other Income / Expenses | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Income Before Tax | (130.47M) | (135.84M) | (152.63M) | (171.97M) | (278.37M) |
| Pre-Tax Margin | — | — | — | -319.1% | -412.5% |
| Income Tax Expense | 0 | 0 | 0 | 2.02M | 297K |
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Net Margin | — | — | — | -322.9% | -412.9% |
| EPS (Basic) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| EPS (Diluted) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| 66.35M | 66.99M | 73.23M | 86.16M | 87.68M | |
| 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
KURA Earnings Waterfall · TTM
NASDAQ:KURA · Revenue to Net Income
Key Ratios
EPS$-3.35
Gross Margin95.3%
Net Margin-414.6%
P/E Ratio-2.5
P/S Ratio40.7
Analysis
$71.6M of revenue converted into -$294.6M of net income for the selected period. Gross margin is 95.3% and net margin is -414.6%, showing how much revenue survives after costs and taxes. EPS is $-3.35, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3ASR | S-3ASR filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 |
How much revenue does KURA generate?
Kura Oncology, Inc. (KURA) reported $67.48M of revenue in fiscal 2025.
Is KURA profitable?
Kura Oncology, Inc. (KURA) reported -$278.67M of net income, with a net margin of -412.9%.
Continue the stock analysis
Jump to another research area for this company.